Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468684 | 0.91 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL230688 | 0.91 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL31031901 | 0.91 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL1660910 | 0.90 | KMT2A (0.74) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29401182 | 0.89 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL6889085 | 0.89 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL887559 | 0.89 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29458423 | 0.89 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL793384 | 0.88 | KMT2A (0.85) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL28617673 | 0.88 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344428-B | Preparation method and application of tripterine glycoconjugate and nanoparticles | 汕头大学医学院第一附属医院 | 2025-04-15 | — | — | CN | claimed |
| CN-118344428-A | Preparation method and application of tripterine glycoconjugate and nanoparticles | 汕头大学医学院第一附属医院 | 2024-07-16 | — | — | CN | claimed |
| EP-3125943-B1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX BV (NL) | 2026-01-22 | — | — | US | disclosed |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4658318-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | Synaffix B.V. (NL) | 2025-12-10 | — | — | EP | disclosed |
| US-12351652-B2 | Hemagglutinin-binding peptide | PEPTIDREAM INC. (JP) | 2025-07-08 | — | — | US | disclosed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025124486-A1 | GLP-1 RECEPTOR COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2025098422-A1 | MULTI-RECEPTOR CO-AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| WO-2025092778-A1 | GLP-1 COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| WO-1995005200-A1 | DRUG DELIVERY AGENTS INCORPORATING MITOMYCIN | EUROPEAN COMMUNITY (LU) | 1995-02-23 | — | — | WO | disclosed |
| EP-0637309-A1 | METAL COATINGS | BIOCOMPATIBLES LIMITED (GB) | 1995-02-08 | — | — | EP | disclosed |
| EP-0399330-B1 | Modified phosphoramidite process for preparing modified nucleic acids | BOEHRINGER MANNHEIM GMBH (DE) | 1994-12-28 | — | — | EP | disclosed |
| EP-0601041-A1 | POLYMER TREATMENTS | BIOCOMPATIBLES LIMITED (GB) | 1994-06-15 | — | — | EP | disclosed |
| WO-1993022320-A1 | METAL COATINGS | BIOCOMPATIBLES LIMITED (GB) | 1993-11-11 | — | — | WO | disclosed |
| EP-0556216-A1 | PHOSPHORIC ACID ESTERS AND THEIR USE IN THE PREPARATION OF BIOCOMPATIBLE SURFACES. | BIOCOMPATIBLES LTD (GB) | 1993-08-25 | — | — | EP | disclosed |
| WO-1993005081-A1 | POLYMER TREATMENTS | BIOCOMPATIBLES LTD. (GB) | 1993-03-18 | — | — | WO | disclosed |
| WO-1992007858-A1 | PHOSPHORIC ACID ESTERS AND THEIR USE IN THE PREPARATION OF BIOCOMPATIBLE SURFACES | BIOCOMPATIBLES LIMITED (GB) | 1992-05-14 | — | — | WO | disclosed |
| EP-0399330-A1 | Modified phosphoramidite process for preparing modified nucleic acids | Roche Diagnostics GmbH (DE) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | FCGR2A, FCGR3B, FCGR1A | KMT2A 1409/4885EPHX2 777/4885FABP7 4601/4885 |
| US-12351652-B2 | Hemagglutinin-binding peptide | HGFAC, HM13, HIRA | KMT2A 437/4885EPHX2 2653/4885FABP7 2308/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | KMT2A 710/4885EPHX2 4662/4885FABP7 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.